Alpha Tau Medical (DRTS) Common Equity (2020 - 2026)

Alpha Tau Medical has disclosed Common Equity across 7 years of filings, most recently posting $69.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $69.4 million, up 23.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.4 million (up 23.13% YoY), and the FY2025 annual result was $77.1 million, up 23.03% from the prior year.
• Common Equity came in at $69.4 million for Q1 2026 at Alpha Tau Medical, down from $77.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $105.7 million in Q4 2022 to a low of $56.3 million in Q1 2025.
• The 5-year median for Common Equity is $78.3 million (2024), against an average of $80.3 million.
• Across the five-year window, Common Equity jumped 403.81% in 2022 and fell 28.76% in 2025, its largest moves.
• Alpha Tau Medical's Common Equity stood at $105.7 million in 2022, then decreased by 20.05% to $84.5 million in 2023, then fell by 25.82% to $62.7 million in 2024, then advanced by 23.03% to $77.1 million in 2025, then retreated by 10.05% to $69.4 million in 2026.
• The last three Common Equity figures came in at $69.4 million (Q1 2026), $77.1 million (Q4 2025), and $77.6 million (Q3 2025), per Business Quant data.